{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:25:47Z","timestamp":1769973947509,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.rdc.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T01:16:54Z","timestamp":1656983814000},"page":"705-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment Guidelines in Vasculitis"],"prefix":"10.1016","volume":"48","author":[{"given":"Tanaz A.","family":"Kermani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha B.","family":"Dua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2022.03.006_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","article-title":"Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides","volume":"17","author":"Jennette","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.rdc.2022.03.006_bib2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 american college of rheumatology\/vasculitis foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/acr.24632","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2022.03.006_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018\u00a0Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib6","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1093\/rheumatology\/kes153","article-title":"Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis","volume":"51","author":"Hauenstein","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib7","doi-asserted-by":"crossref","first-page":"589794","DOI":"10.3389\/fmed.2020.589794","article-title":"Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse","volume":"7","author":"Monti","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.rdc.2022.03.006_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/acr2.11346","article-title":"Vascular ultrasound for giant cell arteritis: establishing a protocol using vascular sonographers in a fast-track clinic in the United States","volume":"4","author":"Oshinsky","year":"2022","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2022.03.006_bib9","doi-asserted-by":"crossref","first-page":"e001297","DOI":"10.1136\/rmdopen-2020-001297","article-title":"Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic","volume":"6","author":"Sebastian","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2022.03.006_bib10","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/modpathol.2017.10","article-title":"Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients","volume":"30","author":"Maleszewski","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.rdc.2022.03.006_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z","article-title":"Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment","volume":"41","author":"Gonzalez-Gay","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2022.03.006_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","article-title":"Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature","volume":"80","author":"Hayreh","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.rdc.2022.03.006_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of Tocilizumab in Giant-Cell Arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2022.03.006_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/kev348","article-title":"Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study","volume":"55","author":"Labarca","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MD.0b013e31821c4fad","article-title":"Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain","volume":"90","author":"Martinez-Lado","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2022.03.006_bib17","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kez672","article-title":"British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis","volume":"59","author":"Mackie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2022.03.006_bib20","first-page":"495","article-title":"A\u00a0prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib22","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/rheumatology\/key040","article-title":"Takayasu arteritis: advanced understanding is leading to new horizons","volume":"58","author":"Tombetti","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11926-020-00955-y","article-title":"Imaging for Diagnosis, Monitoring, and Outcome Prediction of Large Vessel Vasculitides","volume":"22","author":"Schafer","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rdc.2022.03.006_bib26","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System","volume":"10","author":"Strehl","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2022.03.006_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib28","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3899\/jrheum.161269","article-title":"International Delphi on Disease Activity Assessment in Large-vessel V. Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise","volume":"44","author":"Aydin","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib29","doi-asserted-by":"crossref","first-page":"e0145855","DOI":"10.1371\/journal.pone.0145855","article-title":"Vessel Wall Inflammation of Takayasu Arteritis Detected by Contrast-Enhanced Magnetic Resonance Imaging: Association with Disease Distribution and Activity","volume":"10","author":"Kato","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.rdc.2022.03.006_bib30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","article-title":"Comparison of magnetic resonance angiography and (18)F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis","volume":"77","author":"Quinn","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib31","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.10251","article-title":"Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment","volume":"46","author":"Tso","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2022.03.006_bib32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1161\/CIRCULATIONAHA.120.046657","article-title":"Medium- and Large-Vessel Vasculitis","volume":"143","author":"Saadoun","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.rdc.2022.03.006_bib33","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.24633","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2022.03.006_bib34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.41776","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/ard.2008.088096","article-title":"EULAR recommendations for the management of primary small and medium vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.10922","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients","volume":"49","author":"Guillevin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2022.03.006_bib37","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMc1801927","article-title":"Treatment Strategies for Deficiency of Adenosine Deaminase 2","volume":"380","author":"Ombrello","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib39","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2022.03.006_bib40","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib41","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib42","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.rdc.2022.03.006_bib43","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib44","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib45","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib47","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.rdc.2022.03.006_bib48","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/acr2.11230","article-title":"Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta-Analysis of Benefits and Harms of Common Treatments","volume":"3","author":"Springer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.rdc.2022.03.006_bib49","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib50","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","article-title":"Azathioprine or methotrexate maintenance for ANCA-associated vasculitis","volume":"359","author":"Pagnoux","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rdc.2022.03.006_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2022.03.006_bib52","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2022.03.006_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.rdc.2022.03.006_bib54","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","article-title":"Rituximab for eosinophilic granulomatosis with polyangiitis: a systematic review of observational studies","volume":"60","author":"Menditto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2022.03.006_bib55","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2200031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2200031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:29:40Z","timestamp":1760182180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X2200031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0889857X2200031X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2022.03.006","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Guidelines in Vasculitis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}